Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10412407" target="_blank" >RIV/00216208:11110/20:10412407 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/20:10412407 RIV/00064203:_____/20:10412407

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=UPnjbQ31gi" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=UPnjbQ31gi</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/cncr.33055" target="_blank" >10.1002/cncr.33055</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy

Popis výsledku v původním jazyce

A solitary fibrous tumor (SFT) is a rare mesenchymal tumor with a high risk of local recurrence and a metastatic potential. Because of the rarity of the disease, the data regarding possible nonsurgical treatment options are limited. Until recently, most extensive reports regarding nonsurgical SFT treatment were based on case reports. Although SFTs present rare diseases and may have a benign biological nature, local recurrence and metastatic behavior are also highly prevalent. Based on the limited data, we aim to highlight that similarly to soft-tissue sarcomas, radiotherapy, targeted therapy, and immunotherapy should become part of therapeutic algorithms in SFTs. Moreover, clinical testing of other immune checkpoint inhibitors is urgently needed, and only close interdisciplinary cooperation between surgical and nonsurgical institutions can introduce patients with SFTs to novel immunotherapeutic approaches, such as adoptive T-cell transfer and chimeric antigen receptor T-cell immunotherapy.

Název v anglickém jazyce

Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy

Popis výsledku anglicky

A solitary fibrous tumor (SFT) is a rare mesenchymal tumor with a high risk of local recurrence and a metastatic potential. Because of the rarity of the disease, the data regarding possible nonsurgical treatment options are limited. Until recently, most extensive reports regarding nonsurgical SFT treatment were based on case reports. Although SFTs present rare diseases and may have a benign biological nature, local recurrence and metastatic behavior are also highly prevalent. Based on the limited data, we aim to highlight that similarly to soft-tissue sarcomas, radiotherapy, targeted therapy, and immunotherapy should become part of therapeutic algorithms in SFTs. Moreover, clinical testing of other immune checkpoint inhibitors is urgently needed, and only close interdisciplinary cooperation between surgical and nonsurgical institutions can introduce patients with SFTs to novel immunotherapeutic approaches, such as adoptive T-cell transfer and chimeric antigen receptor T-cell immunotherapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer

ISSN

0008-543X

e-ISSN

—

Svazek periodika

126

Číslo periodika v rámci svazku

17

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

4068-4069

Kód UT WoS článku

000545029900001

EID výsledku v databázi Scopus

2-s2.0-85087420076